Business
NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
- NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments - NeuroSense's CEO to present at
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"- NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments\n- NeuroSense's CEO to present at EverythingALS's Expert Talk Series on August 3, 2022; To listen to Mr. Ben-Noon's presentation register here: LINK\nLOS ALTOS, Calif. and CAMBRIDGE, Mass., Aug. 2, 2022 /PRNewswire/ -- EverythingALS, a patient-focused non-profit that brings together patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and data science to support efforts to improve care for those living with a neurological disease like Amyotrophic Lateral Sclerosis (ALS), today announced NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, as a new collaborator in the effort to identify treatments and a cure for ALS.\nEverythingALS was founded in 2020 with the mission of bringing technological innovations and data science to support efforts—from care to cure—for people with ALS. The non-profit conducts technology-based research to help track progression of ALS to be utilized for clinical endpoints. All of the organization's data and insights from research are made available as open science for researchers, pharmaceutical companies, and other potential partners to collaborate.\nNeuroSense is currently enrolling patients in PARADIGM, a Phase IIb double blind, placebo controlled, multicenter clinical trial to evaluate its lead drug candidate for ALS, PrimeC, in Israel and expects to begin patient enrollment in the US and EU this quarter. Top-line results are expected in Q2 2023. PrimeC was tested in a Phase IIa clinical study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and demonstrated statistically significant changes in ALS-related biological markers.\nIn addition to providing financial support for ongoing research projects, NeuroSense's strategic collaboration with EverythingALS will provide insight into patients' needs and allow the company to better serve the ALS community.\n\"We are excited to be working with NeuroSense Therapeutics,\" said Indu Navar, Founder of the Peter Cohen Foundation, functioning as EverythingALS. \"EverythingALS and NeuroSense are taking similar actions in the fight against neu...